GO:0033007 negative regulation of mast cell activation involved in immune response: Regulatory Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0033007 describes any process that stops, prevents, or reduces the frequency, rate, or extent of mast cell activation as part of an immune response.
• Mast cell activation is a central driver of allergic inflammation and anaphylaxis, and its negative regulation is essential for preventing excessive or chronic immune reactions.
• Key negative regulators include the checkpoint molecule Tim-3 (HAVCR2), the microRNA miR-34a, and the cytokine IL-9, which can modulate mast cell responses in context-dependent ways.
• Dysregulation of this process is linked to primary atopic disorders, chronic inflammatory diseases, and tissue remodeling conditions such as cardiac fibrosis.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable precise dissection of genes controlling this regulatory process.
• Bioinformatics and functional genomics approaches are increasingly used to identify novel regulators and immune cell infiltration patterns relevant to this GO term.
Description
Mast cells are tissue-resident innate immune cells that play a central role in allergic reactions, host defense against parasites, and tissue homeostasis. Upon activation through IgE-dependent or IgE-independent mechanisms, they rapidly release histamine, proteases, lipid mediators, and cytokines, which can be protective but also cause severe pathology when uncontrolled. The Gene Ontology term GO:0033007, negative regulation of mast cell activation involved in immune response, captures the biological processes that restrain this activation to maintain immune balance. Understanding this term is critical for researchers studying allergy, autoimmunity, and chronic inflammation, as loss of negative regulation can lead to mast cell-driven diseases. Recent advances in genomic sequencing and bioinformatics have accelerated the identification of primary atopic disorders and immune infiltration signatures linked to mast cell dysregulation. Moreover, emerging evidence implicates microRNAs and checkpoint molecules as key negative regulators of mast cell activation, offering new therapeutic targets. This article provides a research-grade overview of GO:0033007, integrating QuickGO definitions with verified PubMed literature to support experimental design and generative-AI retrieval.
negative regulation of mast cell activation involved in immune response At A Glance
| GO ID | GO:0033007 |
|---|---|
| GO term | negative regulation of mast cell activation involved in immune response |
| Ontology | biological_process |
| Synonym | negative regulation of mast cell activation during immune response |
| Major function | Restrains mast cell activation to prevent excessive allergic and inflammatory responses |
| Related cell type | Mast cells, innate immune cells |
| Key regulators | Tim-3 (HAVCR2), miR-34a, IL-9 |
| Disease relevance | Primary atopic disorders, cardiac fibrosis, chronic inflammation |
| Research methods | CRISPR screens, RNA-seq, bioinformatics, flow cytometry |
What Is GO:0033007?
GO:0033007 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of mast cell activation as part of an immune response. It encompasses molecular mechanisms that dampen mast cell degranulation, cytokine production, and downstream inflammatory signaling during immune reactions. This term is distinct from general mast cell inhibition because it specifically occurs in the context of an active immune response, highlighting its role in immune homeostasis and resolution.
Why Is negative regulation of mast cell activation involved in immune response Important in Cell Biology?
GO:0033007 is important because uncontrolled mast cell activation underlies anaphylaxis, chronic urticaria, and other allergic disorders, while excessive negative regulation may impair host defense. Understanding the molecular players that enforce this negative regulation can reveal therapeutic targets for allergic and inflammatory diseases. Furthermore, this process intersects with tissue remodeling and fibrosis, as mast cell-derived mediators contribute to cardiac fibrosis and other fibrotic conditions. The integration of genomic and bioinformatic approaches has identified novel regulators and immune cell signatures relevant to this GO term, supporting precision medicine efforts.
• Prevents anaphylaxis and severe allergic reactions by limiting mast cell degranulation.
• Maintains immune homeostasis by balancing activating and inhibitory signals.
• Dysregulation is linked to primary atopic disorders and chronic inflammatory diseases.
• Mast cell activation contributes to cardiac fibrosis and tissue remodeling.
• miR-34a and Tim-3 are emerging negative regulators with therapeutic potential.
• IL-9 can modulate mast cell responses, highlighting cytokine-mediated control.
• Bioinformatics analyses reveal immune infiltration patterns associated with this process.
• CRISPR-based models enable functional validation of candidate regulators.
• Supports development of targeted therapies for mast cell-driven diseases.
• Provides a framework for studying immune checkpoint regulation in innate cells.
What Happens During negative regulation of mast cell activation involved in immune response?
Initiation of Negative Regulatory Signals
In simple terms: The body sends 'stop' signals to mast cells to prevent them from overreacting.
Negative regulation begins when inhibitory receptors or soluble factors engage mast cells during an immune response. For example, Tim-3 (HAVCR2) acts as an activation limiter on innate immune cells, including mast cells, by delivering inhibitory signals upon ligand binding. Cytokines such as IL-9 can also modulate mast cell function, sometimes enhancing but in certain contexts restraining activation. These signals set the stage for downstream dampening of mast cell responses.
Inhibition of Degranulation and Mediator Release
In simple terms: The 'stop' signals block the release of histamine and other inflammatory molecules from mast cells.
Once negative regulatory pathways are engaged, they interfere with the machinery of degranulation, reducing the release of histamine, proteases, and lipid mediators. This step is critical for preventing the severe consequences of anaphylaxis and chronic allergic inflammation. Molecular brakes such as microRNAs (e.g., miR-34a) can suppress the expression of genes required for mast cell activation, thereby limiting mediator release.
Suppression of Cytokine and Chemokine Production
In simple terms: The 'stop' signals also reduce the production of inflammatory cytokines that recruit other immune cells.
Activated mast cells produce cytokines and chemokines that amplify immune responses. Negative regulation of this process involves transcriptional and post-transcriptional mechanisms that dampen cytokine synthesis. For instance, miR-34a has been shown to modulate T cell immunity and may similarly affect mast cell cytokine profiles. This suppression prevents excessive immune cell recruitment and tissue damage.
Resolution and Return to Homeostasis
In simple terms: After the threat is controlled, the 'stop' signals help mast cells return to a resting state.
Negative regulation ensures that mast cell activation is transient and resolves once the immune response is no longer needed. This involves the restoration of inhibitory pathways and the clearance of activating stimuli. Failure of this resolution step can lead to chronic mast cell activation and persistent inflammation, as seen in atopic disorders. Understanding these resolution mechanisms is key to developing therapies that promote immune homeostasis.
Key Genes Involved in GO:0033007 negative regulation of mast cell activation involved in immune response
The following genes and proteins have been implicated in the negative regulation of mast cell activation involved in immune response, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| HAVCR2 (Tim-3) | Inhibitory checkpoint receptor that limits innate immune cell activation | Target for modulating mast cell responses in allergy and autoimmunity |
| MIR34A (miR-34a) | MicroRNA that regulates T cell immunity and may suppress mast cell activation | Potential therapeutic mimic or inhibitor for inflammatory diseases |
| IL9 | Cytokine that modulates mast cell function and survival | Context-dependent regulator of allergic inflammation |
| FCER1A | High-affinity IgE receptor subunit; its signaling is subject to negative regulation | Key target for anti-IgE therapies and mast cell desensitization |
| KIT | Receptor tyrosine kinase essential for mast cell survival; negative regulators may dampen its signaling | Imatinib-sensitive target in mastocytosis and related disorders |
| PIK3CD | Phosphoinositide 3-kinase delta; involved in mast cell signaling and can be negatively regulated | Target for PI3K inhibitors in inflammatory diseases |
| PTEN | Phosphatase that negatively regulates PI3K signaling, potentially limiting mast cell activation | Tumor suppressor and immune regulator |
| SHIP1 (INPP5D) | Inositol phosphatase that dampens mast cell activation via FcεRI | Potential target for allergy therapeutics |
| SOCS1 | Suppressor of cytokine signaling; may inhibit mast cell cytokine production | Regulator of cytokine-driven inflammation |
| SOCS3 | Suppressor of cytokine signaling; modulates IL-9 and other cytokine signals | Candidate for controlling mast cell-mediated inflammation |
| TGFB1 | Transforming growth factor beta; can suppress mast cell activation | Fibrosis-related cytokine with immunomodulatory roles |
| IL10 | Anti-inflammatory cytokine that may inhibit mast cell function | Therapeutic potential in allergic diseases |
| FOXP3 | Regulatory T cell transcription factor; Tregs can suppress mast cells | Indirect regulator of mast cell activation |
| CD300A | Inhibitory receptor on mast cells that limits activation | Target for enhancing negative regulation |
| LILRB4 | Inhibitory receptor that can dampen myeloid cell activation | Potential checkpoint for mast cell inhibition |
| ADORA2A | Adenosine receptor that can suppress mast cell degranulation | Target for adenosine-based anti-inflammatory drugs |
| NR4A1 | Nuclear receptor involved in immune regulation and mast cell apoptosis | Candidate for modulating mast cell survival |
| BCL6 | Transcriptional repressor that can inhibit inflammatory gene expression | Potential regulator of mast cell cytokine production |
How Is negative regulation of mast cell activation involved in immune response Regulated?
The negative regulation of mast cell activation is controlled by a network of inhibitory receptors, phosphatases, and microRNAs. Tim-3 (HAVCR2) delivers inhibitory signals that limit innate immune cell activation, including mast cells. miR-34a acts as a post-transcriptional brake on inflammatory pathways in T cells and likely in mast cells. Cytokines such as IL-9 and TGF-β1 can modulate mast cell responses, either enhancing or suppressing activation depending on context. Additionally, phosphatases like SHIP1 and PTEN counteract activating PI3K signals, thereby restraining mast cell degranulation. These regulatory layers ensure that mast cell activation is tightly controlled during immune responses.
negative regulation of mast cell activation involved in immune response and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HAVCR2 (Tim-3) | Primary atopic disorders, autoimmunity | Knockout mouse or human mast cell line with Tim-3 deletion |
| MIR34A | Chronic inflammation, allergy | miR-34a overexpression or knockout in mast cells |
| IL9 | Allergic inflammation, mastocytosis | IL-9 knockout or transgenic mouse models |
| SHIP1 (INPP5D) | Anaphylaxis, allergic asthma | SHIP1 knockout mice or CRISPR-edited mast cells |
| KIT | Mastocytosis, cardiac fibrosis | KIT point-mutation knock-in models |
Primary Atopic Disorders
Primary atopic disorders (PAD) are monogenic conditions characterized by severe allergic inflammation, often due to mutations that impair negative regulation of mast cell activation. Rapid identification of PAD using clinical landmark-guided genomic sequencing has revealed defects in inhibitory pathways, underscoring the importance of GO:0033007 in disease pathogenesis. Patients with PAD may present with eczema, food allergy, and anaphylaxis, highlighting the consequences of failed mast cell restraint.
Cardiac Fibrosis and Tissue Remodeling
Mast cells contribute to cardiac fibrosis through the release of proteases and cytokines that promote fibroblast activation. Negative regulation of mast cell activation is therefore critical to limit fibrotic remodeling after myocardial infarction. Dysregulation of this process can exacerbate fibrosis and lead to heart failure. Targeting mast cell inhibitory pathways may offer therapeutic benefit in fibrotic diseases.
Chronic Inflammatory and Autoimmune Conditions
Loss of negative regulation of mast cell activation is implicated in chronic urticaria, rheumatoid arthritis, and inflammatory bowel disease. Tim-3 dysfunction has been linked to exacerbated innate immune responses, including mast cell-driven inflammation. Restoring inhibitory signals, such as through miR-34a mimics, represents a potential therapeutic strategy.
Renal Stones and Immune Infiltration
Bioinformatics analyses of renal stones have identified aging-related biomarkers and immune infiltration patterns that may involve mast cell activation. Although direct evidence is limited, the interplay between mast cells and the immune microenvironment in kidney stone disease warrants further investigation. Understanding negative regulation in this context could reveal new targets for prevention.
From negative regulation of mast cell activation involved in immune response-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate mast cell activation? | CRISPR knockout in human mast cell line (e.g., HMC-1) |
| Does a specific point mutation in gene Y alter inhibitory function? | Point-mutation knock-in via CRISPR in primary mast cells |
| Can overexpression of gene Z suppress mast cell degranulation? | Lentiviral overexpression in mouse bone marrow-derived mast cells |
| How does tagged protein W localize during negative regulation? | Tagged knock-in (e.g., GFP) using CRISPR |
| What is the role of miR-34a in mast cell cytokine production? | miR-34a knockout and overexpression models |
| Can Tim-3 activation limit anaphylaxis in vivo? | Tim-3 agonist treatment in mouse passive cutaneous anaphylaxis model |
How to Study the negative regulation of mast cell activation involved in immune response Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Loss-of-function effects on mast cell activation | Identify negative regulators |
| RNA-seq | Transcriptional changes during negative regulation | Discover inhibitory pathways |
| Flow cytometry | Degranulation and cytokine production | Validate regulatory genes |
| Phospho-flow | Signaling pathway activity | Assess PI3K/AKT inhibition |
| Proteomics | Protein expression and modifications | Identify effector networks |
| Bioinformatics (GEO) | Immune infiltration and gene signatures | Link to disease datasets |
| miRNA mimic/inhibitor | Post-transcriptional regulation | Study miR-34a function |
| Passive cutaneous anaphylaxis | In vivo mast cell activation | Test negative regulators in mice |
CRISPR Screening for Negative Regulators
Genome-wide CRISPR knockout screens in mast cell lines can identify genes whose loss enhances activation, revealing negative regulators. Such screens have been instrumental in mapping immune regulatory networks. Hits can be validated by individual knockout and functional assays.
Transcriptomic and Bioinformatics Analysis
RNA-seq of activated versus resting mast cells, combined with bioinformatics, can uncover negative regulatory pathways and immune infiltration signatures. Differential expression of inhibitory receptors and microRNAs can be analyzed. Integration with public datasets (e.g., GEO) enhances discovery.
Flow Cytometry and Functional Assays
Flow cytometry measures mast cell degranulation (e.g., CD107a) and cytokine production to quantify negative regulation. Phospho-flow can assess signaling pathways such as PI3K/AKT. These assays are essential for validating CRISPR-edited cells.
Proteomics and Phosphoproteomics
Mass spectrometry-based proteomics can identify changes in protein expression and phosphorylation upon negative regulation. This approach reveals downstream effectors of inhibitory receptors like Tim-3. Phosphoproteomics can pinpoint signaling nodes that are dampened.
How CRISPR Can Be Used to Study GO:0033007 negative regulation of mast cell activation involved in immune response
Knockout
CRISPR knockout of candidate negative regulators (e.g., HAVCR2, INPP5D) in mast cell lines or primary cells can reveal their role in restraining activation. Loss of function typically leads to enhanced degranulation and cytokine release, confirming negative regulatory activity. Knockout models are essential for validating hits from screens.
Point Mutation
Point mutations can be introduced to mimic disease-associated variants or to abrogate specific domains (e.g., phosphatase activity of SHIP1). This allows precise dissection of molecular mechanisms underlying negative regulation. CRISPR prime editing or homology-directed repair enables such modifications.
Knock-in
Knock-in of tagged proteins (e.g., GFP-Tim-3) or reporter cassettes allows real-time tracking of negative regulator localization and expression. Knock-in of human disease alleles into mouse models can recapitulate atopic phenotypes. This approach is valuable for studying dynamic regulation.
Overexpression
Overexpression of negative regulators (e.g., miR-34a, SOCS1) via lentiviral vectors can suppress mast cell activation. This strategy is useful for gain-of-function studies and therapeutic proof-of-concept. Overexpression models complement knockout approaches.
How EDITGENE Supports negative regulation of mast cell activation involved in immune response Research
Researchers studying negative regulation of mast cell activation involved in immune response-related genes often need to determine whether a candidate gene is causally involved in restraining mast cell function. EDITGENE provides end-to-end CRISPR services to accelerate this discovery, from knockout to knock-in and library screening.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of mast cell activation involved in immune response research.
Frequently Asked Questions About negative regulation of mast cell activation involved in immune response
What is GO:0033007?
GO:0033007 is a Gene Ontology biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of mast cell activation as part of an immune response.
What genes are involved in negative regulation of mast cell activation?
Key genes include HAVCR2 (Tim-3), MIR34A, IL9, SHIP1 (INPP5D), and SOCS1, among others.
Why is negative regulation of mast cell activation important?
It prevents excessive allergic reactions, anaphylaxis, and chronic inflammation by restraining mast cell degranulation and cytokine release.
What diseases are linked to defective negative regulation of mast cell activation?
Primary atopic disorders, cardiac fibrosis, chronic urticaria, and autoimmune conditions have been associated with impaired negative regulation.
How can I study negative regulation of mast cell activation?
CRISPR knockout, point-mutation, knock-in, overexpression models, RNA-seq, and flow cytometry are commonly used.
What is the role of Tim-3 in mast cell activation?
Tim-3 (HAVCR2) acts as an activation limiter on innate immune cells, including mast cells, by delivering inhibitory signals.
How does miR-34a regulate mast cell activation?
miR-34a is a microRNA that modulates T cell immunity and may suppress inflammatory pathways in mast cells, though direct evidence is still emerging.
Can CRISPR screens identify new negative regulators of mast cells?
Yes, genome-wide CRISPR knockout screens in mast cell lines can uncover genes whose loss enhances activation, revealing negative regulators.
What is the connection between mast cells and cardiac fibrosis?
Mast cell-derived mediators promote fibroblast activation and fibrosis; negative regulation limits this process.
How does IL-9 affect mast cells?
IL-9 is a cytokine that can modulate mast cell function and survival, with context-dependent effects on activation.
Conclusion
GO:0033007, negative regulation of mast cell activation involved in immune response, is a critical biological process that maintains immune homeostasis and prevents allergic and inflammatory pathology. Key regulators such as Tim-3, miR-34a, and SHIP1 provide molecular brakes on mast cell activation, and their dysfunction is linked to primary atopic disorders and fibrosis. Advances in CRISPR modeling and bioinformatics are accelerating the discovery of new regulatory mechanisms, offering promising avenues for therapeutic intervention. Continued research into this GO term will deepen our understanding of mast cell biology and improve treatment options for mast cell-driven diseases.
References
- 1. Frangogiannis NG. 2019. Cardiac fibrosis: Cell biological mechanisms, molecular pathways and therapeutic opportunities.. Mol Aspects Med 65:70-99 PMID: 30056242
- 2. Niehues T et al.. 2024. Rapid identification of primary atopic disorders (PAD) by a clinical landmark-guided, upfront use of genomic sequencing.. Allergol Select 8:304-323 PMID: 39381601
- 3. Wang Y et al.. 2025. Identification of aging-related biomarkers and immune infiltration analysis in renal stones by integrated bioinformatics analysis.. Sci Rep 15(1):21650 PMID: 40593989
- 4. Tete S et al.. 2012. Interleukin-9 and mast cells.. J Biol Regul Homeost Agents 26(3):319-26 PMID: 23034251
- 5. Taheri F et al.. 2020. Regulatory and immunomodulatory role of miR-34a in T cell immunity.. Life Sci 262:118209 PMID: 32763292
- 6. Han G et al.. 2013. Tim-3: an activation marker and activation limiter of innate immune cells.. Front Immunol 4:449 PMID: 24339828
- 8. Chen K et al.. 2023. Analysis of the role of glucose metabolism-related genes in dilated cardiomyopathy based on bioinformatics.. J Thorac Dis 15(7):3870-3884 PMID: 37559624
